| Popis: |
INTRODUCTION: Multiple myeloma (MM) is the most common malignant plasma cell disease (1). Advances in treatment in the last 10 years have enabled longer overall survival and progression-free survival. Despite these advances in treatment, patients who are followed up without treatment recur after autologous stem cell transplant (ASCT). Maintenance therapy strategies have been introduced to delay relapse. We wanted to share the results of patients with MM, for whom we applied lenalidomide maintenance therapy in our center. METHODS: Between January 2018-January 2020, 22 patients were included in the study, who were diagnosed with MM and received ASCT, and were ineligible for transplantation, started lenalidomide maintenance treatment after induction treatment. RESULTS: Five of the patients developed neutropenia (20%), three of them developed thrombocytopenia (12%), and nine of them developed pneumonia (36%). The maintenance treatment was discontinued in eight of the patients (32%), due to infection, progression of the disease and toxicity. Fourth line treatments was started in patients who discontinued lenalidomide. In the end, one patient died due to the progressive disease (4%). It was followed that one patient was stable disease, six were complete remission, the other six were partial remission, and 11 patients were very good partial remission to the treatment. Patients received lenalidomide maintenance treatment from two months the least, and 44 months (median 12 months) the most. DISCUSSION AND CONCLUSION: Therefore, we recommend that, after induction and consolidation treatments, patients should keep receiving maintenance treatments, as long as there is no progression in the symptoms of the disease, and patients can tolerate. |
